ACR适宜性标准®:胰腺导管腺癌的筛查、局部区域评估与监测2025更新版
该指南由美国放射学会(ACR)制定,基于GRADE与RAND/UCLA适宜性方法,系统综述同行评议文献,针对胰腺导管腺癌的筛查、局部区域及转移评估、手术规划和新辅助治疗及术后监测,给出各影像模态的适用性推荐。
要点
- 影像在胰腺导管腺癌诊断、局部区域与转移评估、手术规划及新辅助治疗和术后监测中起关键作用。
- 指南为每种临床场景汇总当前证据,支持不同影像模态的选用。
- 推荐基于GRADE等系统方法评估证据,文献不足或模棱两可时专家意见可作为主要证据来源。
核心结论
- 指南针对胰腺导管腺癌的筛查、局部区域评估与监测,基于证据汇总了各临床场景下应优先使用的影像模态。
研究设计与样本
- 美国放射学会适宜性标准由多学科专家小组每年审查,采用GRADE等系统方法分析同行评议文献,并依据RAND/UCLA适宜性方法用户手册确定特定临床场景下影像与治疗程序的适宜性。
临床应用与阅片要点
- 在同行评议文献缺乏或模棱两可时,专家意见可作为形成推荐的主要证据来源,临床应结合具体场景选用适宜影像模态。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Pancreatic ductal adenocarcinoma is a highly lethal cancer that often presents with vague and indolent symptoms leading to advanced stage diagnosis. Imaging plays a crucial role in the diagnosis, assessment of locoregional and metastatic disease, surgical planning, and surveillance after neoadjuvant therapy and surgery. This document reviews available imaging modalities that are best used for these clinical scenarios, and a summary of current evidence is provided to support the use of the various modalities in each of the clinical contexts. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision process support the systematic analysis of the medical literature from peer reviewed journals. Established methodology principles such as Grading of Recommendations Assessment, Development, and Evaluation or GRADE are adapted to evaluate the evidence. The RAND/UCLA Appropriateness Method User Manual provides the methodology to determine the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where peer reviewed literature is lacking or equivocal, experts may be the primary evidentiary source available to formulate a recommendation.
引用
- Fung A, Zaheer A, Porter KK, et al. ACR Appropriateness Criteria® Screening, Locoregional Assessment, and Surveillance of Pancreatic Ductal Adenocarcinoma: 2025 Update. J Am Coll Radiol. 2025. PMID: 41193048. doi:10.1016/j.jacr.2025.08.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。